Regeneron reported another strong quarter for Dupixent, driven by label expansions and continued demand across approved indications, with worldwide sales reaching $6 billion for the first time in the second quarter. The rebound follows a period of slower growth and fueled group-wide revenue gains. Regeneron also said it repaid its Sanofi development balance of $3.1 billion, reducing its reported collaboration revenue going forward. Separately, the companies’ CEOs indicated they are in early stages of discussions about expanding their Dupixent collaboration into additional assets that could fit the IL-4/13 portfolio. The updates highlight both near-term commercialization momentum and longer-term business strategy around how to reinvest in follow-on indications as growth faces stronger annual comparisons in the second half of 2026.